LAS
CRSP icon

Lloyd Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Lloyd Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53K Buy
+28
New +$1.48K ﹤0.01% 541
2026
Q1 		– Sell
-28
Closed -$1.47K – 890
2025
Q4 		$1.47K Buy
+28
New +$1.68K ﹤0.01% 465

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lloyd Advisory Services's CRSP Position: Q2 2026 in Review

Lloyd Advisory Services opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 28 shares worth $1.53K. The stake represents ﹤0.01% of the portfolio and ranks #541 among its holdings. This is a return to the name: Lloyd Advisory Services previously reported a position in CRSP as recently as Q4 2025.

Lloyd Advisory Services first reported a position in CRSP in Q4 2025 and has held it in 2 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Lloyd Advisory Services held 28 shares of CRISPR Therapeutics worth $1.53K as of Q2 2026.
  • CRISPR Therapeutics was a new Lloyd Advisory Services position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Lloyd Advisory Services's portfolio in Q2 2026, its #541 holding.
  • Lloyd Advisory Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Lloyd Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.